(Q26801661)

1

0 references

James F Donohue

2

0 references

Peter Kardos

3

0 references

David Price

Expert Opinion on Pharmacotherapy

5

0 references

language of work or name

English

0 references

publication date

2015

0 references

published in

1 reference

17 November 2019

16

0 references

page(s)

1845-60

0 references

issue

12

0 references

copyright license

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

1 reference

Europe PubMed Central

Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis

17 November 2019

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Combined corticosteroid and long-acting beta 2 -agonist in one inhaler versus placebo for chronic obstructive pulmonary disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Inhaled corticosteroids in COPD: the clinical evidence

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Quantifying the real life risk profile of inhaled corticosteroids in COPD by record linkage analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

The asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

The clinical and genetic features of COPD-asthma overlap syndrome

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Recent advances in COPD disease management with fixed-dose long-acting combination therapies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: A systematic review and meta-analysis of randomized controlled trials. a systematic review and meta-analysis of randomized controlled trials.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

GOLD 2011 disease severity classification in COPDGene: a prospective cohort study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

The distribution of COPD in UK general practice using the new GOLD classification.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Inhaled corticosteroids in COPD and the risk of serious pneumonia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Long-acting beta-agonists and their association with inhaled corticosteroids in COPD.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

The excessive use of inhaled corticosteroids in chronic obstructive pulmonary disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Inhaled corticosteroids and the risks of diabetes onset and progression

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Methodological issues in therapeutic trials of COPD.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Characterisation of the frequent exacerbator phenotype in COPD patients in a large UK primary care population

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

TORCH and UPLIFT: what has been learned from the COPD "mega-trials"?

31 May 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Understanding the GOLD 2011 Strategy as applied to a real-world COPD population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Skin manifestations of inhaled corticosteroids in COPD patients: results from Lung Health Study II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Effect of combination treatment on lung volumes and exercise endurance time in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Prediction of treatment-response to inhaled corticosteroids by mannitol-challenge test in COPD. A proof of concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Sputum inflammation predicts exacerbations after cessation of inhaled corticosteroids in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Eosinophilic inflammation in COPD: prevalence and clinical characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Factors associated with bronchiectasis in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Corticoides inhalados en la EPOC por fenotipo en lugar de por gravedad. Argumentos a favor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Prediction of the Clinical Course of Chronic Obstructive Pulmonary Disease, Using the New GOLD Classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Use of inhaled corticosteroids and the risk of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

Spanish guideline for COPD (GesEPOC). Update 2014.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673525

Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long-term inhaled corticosteroid treatment. Dutch CNSLD Study Group

28 November 2018

1 reference

12 December 2020

Methodological issues in therapeutic trials of COPD

1 reference

12 December 2020

Chronic obstructive pulmonary disease

1 reference

12 December 2020

Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease

1 reference

12 December 2020

Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease

1 reference

12 December 2020

An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group

1 reference

12 December 2020

Low-dose inhaled and nasal corticosteroid use and the risk of cataracts

1 reference

12 December 2020

The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group

1 reference

12 December 2020

Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease

1 reference

12 December 2020

Stepping down therapy in COPD

1 reference

12 December 2020

Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group

1 reference

12 December 2020

Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia

1 reference

12 December 2020

What was the impact of the Spanish COPD guidelines (GesEPOC) and how can they be improved?

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067682

7 January 2021